Terms: = Prostate cancer AND PSA AND Staging
1376 results:
1. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract] [Full Text] [Related]
2. A pictorial view on false positive findings of
Dancheva Z; Chausheva S; Stoeva T; Dyankova M; Yordanova T; Chaushev B; Marinov R; Nikolov V; Abushev P; Todorov G; Dimitrova E; Klisarova A; Anakievski D
Hell J Nucl Med; 2024; 27(1):16-26. PubMed ID: 38629815
[TBL] [Abstract] [Full Text] [Related]
3. Is Unilateral Lymphadenectomy an Option in Selected Patients with prostate cancer?
Kassab BN; De Pablos-Rodríguez P; Ferrer ÁG; García AC; Fons AC; Aragón F; Ramón-Borja JC; Ramírez-Backhaus M
Arch Esp Urol; 2024 Mar; 77(2):129-134. PubMed ID: 38583004
[TBL] [Abstract] [Full Text] [Related]
4. Comparison of Ga-PSMA PET MRI with mpMRI in localization and regional staging of prostate cancer.
Deka H; Pooleri GK; Suguna B; Rajeshkannan R; Sekhar R; Bindhu MR; Prasad V
World J Urol; 2024 Mar; 42(1):153. PubMed ID: 38483621
[TBL] [Abstract] [Full Text] [Related]
5. [
Li B; Ding X; Duan L; Shi J; Tang M; Zhang J; Zhao Z; Wu X; Gao Y
Front Endocrinol (Lausanne); 2024; 15():1326858. PubMed ID: 38449842
[TBL] [Abstract] [Full Text] [Related]
6. Ductal prostate cancer staging: Role of PSMA PET/CT.
Pepe P; Pepe L; Curduman M; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2024 Feb; 96(1):12132. PubMed ID: 38363231
[TBL] [Abstract] [Full Text] [Related]
7. prostate cancer: Novel genetic and immunologic biomarkers.
Samare-Najaf M; Kouchaki H; Moein Mahini S; Saberi Rounkian M; Tavakoli Y; Samareh A; Karim Azadbakht M; Jamali N
Clin Chim Acta; 2024 Mar; 555():117824. PubMed ID: 38316287
[TBL] [Abstract] [Full Text] [Related]
8. prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO).
Koerber SA; Höcht S; Aebersold D; Albrecht C; Boehmer D; Ganswindt U; Schmidt-Hegemann NS; Hölscher T; Mueller AC; Niehoff P; Peeken JC; Pinkawa M; Polat B; Spohn SKB; Wolf F; Zamboglou C; Zips D; Wiegel T
Strahlenther Onkol; 2024 Mar; 200(3):181-187. PubMed ID: 38273135
[TBL] [Abstract] [Full Text] [Related]
9. Contribution of 68 Ga-DOTA-FAPI-04 PET/CT to prostate cancer Imaging : Complementary Role in PSMA-Negative Cases.
Ergül N; Çermik TF; Alçın G; Arslan E; Erol Fenercioğlu Ö; Beyhan E; Şahin R; Baloğlu MC; Baykal Koca S; Türkay R; Yücetaş U
Clin Nucl Med; 2024 Mar; 49(3):e105-e110. PubMed ID: 38271254
[TBL] [Abstract] [Full Text] [Related]
10. Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients.
Falkenbach F; Kachanov M; Leyh-Bannurah SR; Maurer T; Knipper S; Köhler D; Graefen M; Sauter G; Budäus L
World J Urol; 2024 Jan; 42(1):38. PubMed ID: 38244095
[TBL] [Abstract] [Full Text] [Related]
11. Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
Ozawa Y; Nohara S; Nakamura K; Hattori S; Yagi Y; Nishiyama T; Yorozu A; Monma T; Saito S
Prostate; 2024 Apr; 84(5):502-510. PubMed ID: 38173289
[TBL] [Abstract] [Full Text] [Related]
12. Less qualitative multiparametric magnetic resonance imaging in prostate cancer can underestimate extraprostatic extension in higher grade tumors.
Schmit S; Allu S; Tanzer JR; Ortiz R; Pareek G; Hyams E
Int Braz J Urol; 2024; 50(1):37-45. PubMed ID: 38166221
[TBL] [Abstract] [Full Text] [Related]
13. Investigation of radiomics models for predicting biochemical recurrence of advanced prostate cancer on pretreatment MR ADC maps based on automatic image segmentation.
Wang H; Wang K; Ma S; Gao G; Wang X
J Appl Clin Med Phys; 2024 Apr; 25(4):e14244. PubMed ID: 38146796
[TBL] [Abstract] [Full Text] [Related]
14. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer.
Madendere S; Kılıç M; Köseoğlu E; Aykanat İC; Eden AB; Coşkun B; Tekkalan FB; Balbay MD
Urol Oncol; 2024 Feb; 42(2):29.e9-29.e15. PubMed ID: 38114351
[TBL] [Abstract] [Full Text] [Related]
15. The Brazilian national prospective active surveillance (AS) cohort of patients with low-risk prostate cancer in the public health system: vigiaSUS study protocol.
Basso J; de Lima JB; Bessel M; Tobar Leitão SA; Machado Baptista T; Roithmann S; Franco Carvalhal E; da Silva Schmitt C; Morzoletto Pedrollo I; Schuch A; Atalibio Hartmann A; Neubarth Estivallet CL; Behrend Silva Ribeiro G; Zordan RA; Isaacsson Velho P
BMC Urol; 2023 Dec; 23(1):208. PubMed ID: 38082337
[TBL] [Abstract] [Full Text] [Related]
16. 68 Ga-PSMA-11 PET/CT and 64 CuCl 2 PET/CT Help in Identifying Rare Metastatic Site of Penile Shaft in a Patient of Carcinoma prostate.
Verma P; Nazar A; Jadhav S; Basu S
Clin Nucl Med; 2024 Jan; 49(1):e10-e11. PubMed ID: 37976433
[TBL] [Abstract] [Full Text] [Related]
17. Cost-Effectiveness Modeling of prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with prostate cancer in the United States.
Yee CW; Harvey MJ; Xin Y; Kirson NY
Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
[TBL] [Abstract] [Full Text] [Related]
18. prostate cancer Disparities in Metastatic and Treatment Status for Hispanic Americans Based on Country of Origin Compared to Non-Hispanic Whites Using the National cancer Database.
Estrada-Mendizabal RJ; Dhaliwal AS; Bertolo AJ; Batai K; Heimark R; Recio-Boiles A; Chipollini J
Clin Genitourin Cancer; 2024 Feb; 22(1):e148-e155.e1. PubMed ID: 37903669
[TBL] [Abstract] [Full Text] [Related]
19. Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence.
Hou Y; Jiang KW; Wang LL; Zhi R; Bao ML; Li Q; Zhang J; Qu JR; Zhu FP; Zhang YD
Br J Cancer; 2023 Nov; 129(10):1625-1633. PubMed ID: 37758837
[TBL] [Abstract] [Full Text] [Related]
20. Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic prostate cancer: Comparative Analysis in Terms of CRPC-M0 Progression.
Salciccia S; Frisenda M; Tufano A; Di Pierro G; Bevilacqua G; Rosati D; Gobbi L; Basile G; Moriconi M; Mariotti G; Forte F; Carbone A; Pastore A; Cattarino S; Sciarra A; Gentilucci A
Clin Genitourin Cancer; 2024 Apr; 22(2):74-83. PubMed ID: 37758559
[TBL] [Abstract] [Full Text] [Related]
[Next]
